Advances in non-apoptotic regulated cell death: implications for malignant tumor treatment.

IF 3.5 3区 医学 Q2 ONCOLOGY Frontiers in Oncology Pub Date : 2025-01-30 eCollection Date: 2025-01-01 DOI:10.3389/fonc.2025.1519119
Yizheng Zhang, Shiqi Yi, Mingyuan Luan
{"title":"Advances in non-apoptotic regulated cell death: implications for malignant tumor treatment.","authors":"Yizheng Zhang, Shiqi Yi, Mingyuan Luan","doi":"10.3389/fonc.2025.1519119","DOIUrl":null,"url":null,"abstract":"<p><p>Cell death mechanisms are broadly classified into accidental cell death (ACD) and regulated cell death (RCD). ACD such as necrosis, is an uncontrolled, accidental process, while RCD is tightly regulated by specific signaling pathways and molecular mechanisms. Tumor cells are characterized by their ability to evade cell death and sustain uncontrolled proliferation. The failure of programmed cell death is a key contributor to tumor initiation, progression, and resistance to cancer therapies. Traditionally, research has focused primarily on apoptosis as the dominant form of RCD in cancer. However, emerging evidence highlights the importance of other non-apoptotic forms of RCD, such as pyroptosis, ferroptosis, necroptosis, and parthanatos, in tumorigenesis and treatment response. These pathways are gaining attention for their potential roles in overcoming therapy resistance. In this review, we will discuss the recent advances in the study of non-apoptotic cell death pathways in malignant tumors and explore their therapeutic implications, offering insights into new targets for cancer treatment strategies.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1519119"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821507/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1519119","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cell death mechanisms are broadly classified into accidental cell death (ACD) and regulated cell death (RCD). ACD such as necrosis, is an uncontrolled, accidental process, while RCD is tightly regulated by specific signaling pathways and molecular mechanisms. Tumor cells are characterized by their ability to evade cell death and sustain uncontrolled proliferation. The failure of programmed cell death is a key contributor to tumor initiation, progression, and resistance to cancer therapies. Traditionally, research has focused primarily on apoptosis as the dominant form of RCD in cancer. However, emerging evidence highlights the importance of other non-apoptotic forms of RCD, such as pyroptosis, ferroptosis, necroptosis, and parthanatos, in tumorigenesis and treatment response. These pathways are gaining attention for their potential roles in overcoming therapy resistance. In this review, we will discuss the recent advances in the study of non-apoptotic cell death pathways in malignant tumors and explore their therapeutic implications, offering insights into new targets for cancer treatment strategies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非凋亡调节细胞死亡的研究进展:对恶性肿瘤治疗的意义。
细胞死亡机制大致分为意外细胞死亡(ACD)和调节细胞死亡(RCD)。坏死等ACD是一个不受控制的偶然过程,而RCD则受到特定信号通路和分子机制的严格调控。肿瘤细胞的特点是它们有能力逃避细胞死亡和维持不受控制的增殖。程序性细胞死亡的失败是肿瘤发生、发展和对癌症治疗产生耐药性的关键因素。传统上,研究主要集中在细胞凋亡作为RCD在癌症中的主要形式。然而,新出现的证据强调了其他非凋亡形式的RCD在肿瘤发生和治疗反应中的重要性,如焦下垂、铁下垂、坏死性下垂和旁咽下。这些途径因其在克服治疗耐药性方面的潜在作用而受到关注。在这篇综述中,我们将讨论恶性肿瘤中非凋亡细胞死亡途径的最新研究进展,并探讨其治疗意义,为癌症治疗策略的新靶点提供见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Oncology
Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
6.20
自引率
10.60%
发文量
6641
审稿时长
14 weeks
期刊介绍: Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.
期刊最新文献
Patient with AL amyloidosis with recurrent syncope as the first symptom: case report and literature review. Management of dysphagia in head and neck cancer: current and future perspectives. Recent advances in drug repurposing for cancer immunomodulation emerging strategies, mechanistic insights, and clinical translation. Robot-assisted partial nephrectomy for TFE3-rearranged renal cell carcinoma: a case report and literature review. Risk management in the dual crisis of unresectable colorectal cancer and deep vein thrombosis: navigating between hemorrhage and antithrombosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1